Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.017 | 0.7 |
mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | PF-543 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.028 | 0.7 |